Table 1 Clinical covariates for KORA, NAS, and InCHIANTI
a. Clinical covariates at baseline and follow-up exams | ||||||
KORA | NAS | InCHIANTI | ||||
Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
N | 1103 | 1103 | 344 | 344 | 443 | 443 |
N MI | – | 13 | – | 14 | – | 50 |
Time to MI—years; mean (SD) | – | 4.08 (2.2) | – | 2.76 (1.3) | – | 6.47 (2.9) |
FU time—years; mean (SD) | – | 7.10 (0.22) | – | 8.52 (3.2) | – | 9.12 (0.21) |
Age—years; mean (SD) | 54.5 (8.87) | 61.5 (8.9) | 70.9 (6.6) | 74.5 (6.6) | 61.7 (16.2) | 70.8 (16.2) |
Males—N (%) | 558 (50.6%) | 558 (50.6%) | 100% | 100% | 206 (46.5%) | 206 (46.5%) |
BMI—kg/m2; mean (SD) | 27.7 (4.5) | 28.1 (4.8) | 28.1 (4.1) | 27.7 (4.1) | 27.0 (3.9) | 27.0 (4.3) |
Current smokers—N (%) | 212 (19.2%) | 161 (14.6%) | 17 (4.94%) | 16 (4.65%) | 89 (20.1%) | 45 (10.2%) |
Former smokers—N (%) | 417 (37.8%) | 469 (42.5%) | 220 (64.0%) | 222 (64.5%) | 105 (23.7%) | 151 (34.1%) |
LDL-C—mg/dL; mean (SD) | 144 (40.1) | 140 (35.8) | – | – | 135 (35.9) | 124 (31.8) |
HDL-C—mg/dL; mean (SD) | 57.5 (16.9) | 56.2 (14.8) | 51.3 (14.1) | 50.6 (13.5) | 56.1 (14.2) | 56.5 (15.2) |
Hypertension—N (%) | 484 (44.2%) | 522 (47.4%) | 209 (60.8%) | 232 (67.4%) | 221 (49.9%) | 247 (55.8%) |
Type 2 diabetes—N (%) | 39 (3.54%) | 105 (9.53%) | 36 (10.5%) | 48 (14.0%) | 38 (8.6%) | 49 (11.1%) |
b. Clinical covariates at baseline for individuals who did not develop an MI (controls) vs those who did (cases) | ||||||
KORA | NAS | InCHIANTI | ||||
Controls | Cases | Controls | Cases | Controls | Cases | |
N | 1090 | 13 | 330 | 14 | 393 | 50 |
Age—years; mean (SD) | 54.4 (8.9) | 58.9 (7.2) | 70.9 (6.5) | 69.3 (8.4) | 60.9 (16.7) | 67.8 (9.4) |
Males—N (%) | 548 (50.3%) | 10 (76.9%) | 100% | 100% | 181 (46.1%) | 25 (50.0%) |
BMI—kg/m2; mean (SD) | 27.7 (4.4) | 31 (7.1) | 28.0 (4.1) | 29.0 (4.0) | 26.9 (3.9) | 27.3 (3.46) |
Current smokers—N (%) | 208 (19.1%) | 4 (30.8%) | 16 (4.84%) | 1 (7.14%) | 80 (20.4%) | 9 (18.0%) |
Former smokers—N (%) | 412 (37.8%) | 5 (38.5%) | 210 (63.6%) | 10 (71.4%) | 88 (22.4%) | 17 (34.0%) |
LDL—mg/dL; mean (SD) | 144 (40.2) | 144 (36.7) | – | – | 134 (35.9) | 144 (34.6) |
HDL—mg/dL; mean (SD) | 57.7 (16.8) | 42 (11.7) | 51.7 (14.1) | 41.7 (8.5) | 56.0 (14.3) | 57.6 (13.2) |
Hypertension—N (%) | 476 (44%) | 8 (61.5%) | 201 (60.9%) | 8 (57.1%) | 187 (47.6%) | 34 (68.0%) |
Type 2 diabetes—N (%) | 37 (3.4%) | 2 (15.4%) | 32 (9.70%) | 4 (28.6%) | 31 (7.9%) | 7 (14.0%) |
c. Clinical covariates at follow-up for individuals who did not develop an MI (controls) vs those who did (cases) | ||||||
KORA | NAS | InCHIANTI | ||||
Controls | Cases | Controls | Cases | Controls | Cases | |
N | 1090 | 13 | 330 | 14 | 393 | 50 |
Time to MI—years; mean (SD) | – | 4.08 (2.2) | – | 2.76 (1.3) | – | 6.47 (2.9) |
FU time—years; mean (SD) | 7.1 (0.22) | 7.2 (0.38) | 8.8 (2.97) | 2.8 (1.3) | 9.1 (0.21) | 9.1 (0.21) |
Age—years; mean (SD) | 61.4 (8.9) | 65.9 (7.2) | 74.5 (6.5) | 73.3 (8.2) | 70.0 (16.7) | 76.9 (9.5) |
Males—N (%) | 548 (50.3%) | 10 (76.9%) | 100% | 100% | 181 (46.1%) | 25 (50.0%) |
BMI—kg/m2; mean (SD) | 28.1 (4.71) | 32.6 (7.24) | 27.7 (4.1) | 28.3 (4.2) | 27.0 (4.35) | 27.0 (3.72) |
Current smokers—N (%) | 159 (14.6%) | 2 (15.4%) | 15 (4.6%) | 1 (7.1%) | 42 (10.7%) | 3 (6.0%) |
Former smokers—N (%) | 462 (42.4%) | 7 (53.8%) | 212 (64.2%) | 10 (71.4%) | 128 (32.6%) | 23 (46.0%) |
LDL-C—mg/dL; mean (SD) | 140 (35.8) | 111 (16.8) | – | – | 123 (31.9) | 127 (31.4) |
HDL-C—mg/dL; mean (SD) | 56.4 (14.8) | 41.5 (10.2) | 51.1 (13.6) | 40.3 (6.0) | 56.4 (15.3) | 57.3 (14.6) |
Hypertension—N (%) | 513 (47.2%) | 9 (69.2%) | 219 (66.3%) | 13 (92.9%) | 216 (55.0%) | 31 (62.0%) |
Type 2 diabetes—N (%) | 98 (9.0%) | 7 (53.8%) | 43 (13.0%) | 5 (35.7%) | 44 (11.2) | 5 (10.0%) |